Ademi LLP is investigating Translate Bio (NASDAQ: TBIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
Ademi LLP alleges Translate Bio’s financial outlook and prospects are excellent and yet Translate Bio shareholders will receive only $38 per share in a cash tender offer. The merger agreement unreasonably limits competing bids for Translate Bio by prohibiting solicitation of further bids, and imposing a penalty of $96 million if Translate Bio accepts a superior bid. Translate Bio insiders will receive millions of dollars as part of change of control arrangements. We are investigating the conduct of Translate Bio’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Translate Bio.